Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 695
  • 448
  • 14
  • 31
  • 1
  • 4
  • 647

Found 697 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 2
The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating patients with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy.
99 years or below
All genders
Phase 2
The main purpose of this study is to investigate the use of a new, experimental drug called JNJ-68284528 in subjects with multiple myeloma.
99 years or below
All genders
Phase 1
Multi-center, open-label, first in human (FIH) Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CARTTnMUC1 cells). …
99 years or below
All genders
Phase 3
The study is an open-label, randomized, parallel group study conducted in patients with histologically confirmed MPM of epithelioid or biphasic (predominantly [50%] epithelioid) histology who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum …
 Study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 subjects with Leber's Congenital Amourosis (LCA) Due to to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.
18 years - 90 years
All genders
Interventional
You are invited to take part in a research study for with the investigational drug, QR-110 (referred to as “the study drug”) for Leber's Congenital Amourosis . Currently there is no approved treatment for LCA10. The study drug is designed to repair the problem that causes LCA10. This may stop …
 An Open Label Study to Assess the Safety and Efficacy of COR-003(2S 4R-Ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
1 years - 99 years
All genders
Phase 3
The purpose of this clinical research study is to find out if the drug COR-003 is safe and has beneficial effects in patients who have Cushings disease and to determine the most effective dosage for each individual subject. . COR-003 is taken in pill form twice a day. The study …
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
 A Phase III  multi-center  double-blind  randomized withdrawal study of LCI699 following a 24 week  single-arm  open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease (PRIME)
1 years - 99 years
All genders
Phase 3
The study aims to confirm the long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease who have had had surgery that has not been successful, or are not a good surgical candidate, or refuse surgery, and have not received radiation treatment for this condition within …
 EFICACIA Y SEGURIDAD DE UN MEDICAMENTO INYECTABLE UNA VEZ A LA SEMANA EN PARTICIPANTES CON SOBREPESO U OBESIDAD. (REDEFINIR 1)
1 years - 99 years
All genders
Phase 3
Este es un estudio de prueba de concepto multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 2 brazos, de grupos paralelos. El objetivo principal de este estudio es evaluar el efecto de dupilumab en el alivio de los síntomas clínicos de la EoE y la reducción de la inflamación esofágica …
 Randomized Controlled Trial Examining the Effects of Meal Timing Among Obese Individuals
21 years - 50 years
All genders
Normal 0 false false false EN-US X-NONE X-NONE We are currently screening for this study, but all in-person visits are on hold until the COVID-19 virus state of emergency is lifted. The timing of food consumption is now recognized as a significant contributor to body weight regulation and metabolic functioning. …
351 - 360 of 697